Search PubMed⌕ Search

PubMed · 9747617

Radioactive decay.

Abstract

When a parent radionuclide decays to its daughter radionuclide by means of alpha, beta, or isomeric transition, the decay follows an exponential form, which is characterized by the decay constant lambda. The decay constant represents the probability per unit time that a single radioatom will decay. The decay equation can be used to provide a useful expression for radionuclide decay, the half-life, the time when 50% of the radioatoms present will have decayed. Radiotracer half-life has direct implications in nuclear imaging, radiation therapy, and radiation safety because radionuclide half-life affects the ability to evaluate tracer kinetics and create appropriate nuclear images and also affects organ, tumor, and whole-body radiation dose. The number of radioatoms present in a sample is equal to the activity, defined as the number of transitions per unit time, divided by the decay constant; the mass of radioatoms present in a sample can be calculated to determine the specific activity (activity per unit mass). The dynamic relationship between the number of parent and daughter atoms present over time may lead to radioactive equilibrium, which takes two forms--secular and transient--and has direct relevance to generator-produced radionuclides.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M W Groch. Radioactive decay.. https://doi.org/10.1148/radiographics.18.5.9747617

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Dissipation of lindane and fenvalerate residues in chickpea (Cicer arietinum L.) under Indian climatic conditions.

Dissipation behavior of lindane 20 EC (400 and 800 g a.i./ha) and fenvalerate 0.4% dust (75 and 150 g a.i./ha) applied on chickpea (var. H 208) for controlling pod borer under field conditions during rabi 1994-1995 at pod initiation stage was studied. Grains from lower dose of lindane at harvest contained residues below maximum residue limit value (0.25 microg g(-1)), whereas no measurable amount of fenvalerate residues were found in grains of both doses at harvest. A waiting period of 7 days for lindane and 1 day for fenvalerate is suggested from point of hazards due to residues, when applied at recommended dose. The residues calculated from consumption of chickpea (60 g/person/day) is much below the maximum permissible intake of lindane and fenvalerate; hence the recommended doses can be considered safe from point of view of hazards to humans.

Half-Life↗

Half-life and X-ray emission probabilities of 55Fe.

The X-ray emission probabilities of the Mn-K(alpha) and Mn-K(beta) radiation in the decay of 55Fe were measured with a calibrated Si(Li) spectrometer, resulting in 0.245(7) and 0.0338(9), respectively. A half-life of 1003.5(21) day was measured using the same detector.

Half-Life↗

Physical and chemical properties of radionuclide therapy.

As more radionuclide therapies move from laboratory feasibility studies into clinical reality, it becomes increasingly important for the labeling chemistry to produce consistently a stable radiopharmaceutical that remains intact under the challenge of human catabolism. Similarly, once proof of principle is established to bring a radionuclide conjugate into clinical therapy trials, dosimetric estimates should be made to select the appropriate radionuclide properties, which are based on animal-specific or patient-specific pharmacokinetics and match a set of specific clinical endpoints. These properties may include the radionuclide physical half-life, radiolabeled conjugate biological uptake and clearance, product-specific activity, range and type of emissions, and resultant effects on tumor and normal tissue cellular survival. The immunologist and labeling chemist have now produced a variety of strategies that have potential to increase the therapeutic ratio (tumor-to-normal tissue dose ratio). The advent of normal tissue clearing agents, fragmented or chimerized carriers to improve targeting, and the method of bispecific or two-step and three-step targeting agents has increased the need for realistic modeling of the carrier in vivo to guide prospectively the competitive development of these radiopharmaceuticals. In this article, examples have been taken from the literature to elucidate the benchmark of success that careful experimental design has fostered to bring these agents into clinical practice by creative and logical methodologies.

Half-Life↗